Son of sevenless homolog 1 (SOS1) inhibitors have been detailed in a Shanghai Allist Pharmaceuticals Co. Ltd. patent and described as useful for the treatment of cancer, arteriovenous malformations, cardiofaciocutaneous syndrome, Costello syndrome, Legius syndrome (neurofibromatosis type 1-like syndrome), neurofibromatosis type 1, Noonan syndrome and Splenomegaly, among others.

Research at Boehringer Ingelheim Pharma GmbH & Co. KG has led to the development of proteolysis targeting chimeras (PROTACs) comprising a Von Hippel-Lindau E3 ubiquitin ligase (VHL)-binding moiety covalently linked to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety through a linker.

A Blacksmith Medicines Inc. patent describes the development of prodrugs of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors reported to be useful for the treatment of complicated urinary tract infections (UTIs).

Turbinmicin analogues reported to be useful for the treatment of fungal infections have been described in a recent Wisconsin Alumni Research Foundation (WARF) patent.

Researchers at Repare Therapeutics Inc. have prepared and tested N-(5-substituted-[(1,3,4-thiadiazolyl) or (thiazolyl)]) (substituted) carboxamide compounds acting as DNA polymerase θ (POLQ) inhibitors and thus reported to be useful or the treatment of cancer.

Janssen R&D (Ireland) has described respiratory syncytial virus (RSV) inhibiting spiro-bearing derivatives reported to be potentially useful for the treatment of RSV infections.

Pyruvate kinase isozyme M2 (PKM2) and pyruvate kinase PKLR activators have been revealed in a Sitryx Therapeutics Ltd. patent.

Research at Nextgen Bioscience Co. Ltd. has led to the identification of ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors.

A recent Hanmi Holdings Co. Ltd. patent describes 1-phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, rheumatoid arthritis and Crohn’s disease.

Humanwell Healthcare (Group) Co. Ltd. researchers have prepared and tested AP2-associated protein kinase 1 (AAK1) inhibitors that are reported to be useful for the treatment of bipolar disorder, pain, schizophrenia, Alzheimer’s and Parkinson’s disease.